MX382748B - Compuestos heterociclicos utiles para el tratamiento de una enfermedad. - Google Patents

Compuestos heterociclicos utiles para el tratamiento de una enfermedad.

Info

Publication number
MX382748B
MX382748B MX2015013303A MX2015013303A MX382748B MX 382748 B MX382748 B MX 382748B MX 2015013303 A MX2015013303 A MX 2015013303A MX 2015013303 A MX2015013303 A MX 2015013303A MX 382748 B MX382748 B MX 382748B
Authority
MX
Mexico
Prior art keywords
diseases
treatment
heterocyclic compounds
ethoxycarbonylamino
fluoro
Prior art date
Application number
MX2015013303A
Other languages
English (en)
Other versions
MX2015013303A (es
Inventor
Chandravadan R Shah
Fabio C Tucci
Graham Beaton
Hiep Liu
Satheesh B Ravula
Original Assignee
Epigen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigen Biosciences Inc filed Critical Epigen Biosciences Inc
Publication of MX2015013303A publication Critical patent/MX2015013303A/es
Publication of MX382748B publication Critical patent/MX382748B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Los compuestos heterocíclicos que se describen son ligandos de receptores de ácido lisofosfatidico que son útiles en el tratamiento de enfermedades y trastornos dependientes del receptor de ácido lisofosfatídico, que incluyen a modo no taxativo, enfermedades asociadas con la fibrosis, como fibrosis del corazón, riñón, hígado y pulmón; esclerodermia; enfermedades inflamatorias, como la nefropatía diabética y la enfermedad inflamatoria intestinal; enfermedades oculares, como enfermedades asociadas con la degeneración de la retina; enfermedades nerviosas, como prurito y dolor. Los ejemplos no taxativos de dichos compuestos incluyen (RS)-3-Ciclopropilo- 2-{4-[3-metil-4-((R)-1-fenilo-etoxicarbonilamino)-isoxazol-5-il)-benciloxi}-ácido propanóico y (R)-l-(4'-{5-[1-(2-Clorofenil)-etoxicarbonilamino]-4-fluoro-pirazol-1-il}-2-fluoro-bifenil-4-il) -ácido ciclopropanocarboxílico.
MX2015013303A 2013-03-15 2014-03-17 Compuestos heterociclicos utiles para el tratamiento de una enfermedad. MX382748B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361801426P 2013-03-15 2013-03-15
US201361801231P 2013-03-15 2013-03-15
US201361827409P 2013-05-24 2013-05-24
PCT/US2014/030712 WO2014145873A2 (en) 2013-03-15 2014-03-17 Heterocyclic compounds useful in the treatment of disease

Publications (2)

Publication Number Publication Date
MX2015013303A MX2015013303A (es) 2015-12-15
MX382748B true MX382748B (es) 2025-03-13

Family

ID=51538557

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015013303A MX382748B (es) 2013-03-15 2014-03-17 Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
MX2020014300A MX2020014300A (es) 2013-03-15 2019-06-18 Compuestos heterociclicos utiles en el tratamiento de enfermedades.
MX2024011839A MX2024011839A (es) 2013-03-15 2020-12-18 Compuetos heterociclicos utiles en el tratamiento de enfermedades.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020014300A MX2020014300A (es) 2013-03-15 2019-06-18 Compuestos heterociclicos utiles en el tratamiento de enfermedades.
MX2024011839A MX2024011839A (es) 2013-03-15 2020-12-18 Compuetos heterociclicos utiles en el tratamiento de enfermedades.

Country Status (15)

Country Link
US (5) US10000459B2 (es)
EP (1) EP2988743B1 (es)
JP (4) JP6482086B2 (es)
KR (1) KR102090231B1 (es)
CN (3) CN105142635B (es)
AU (3) AU2014232383B2 (es)
BR (2) BR112015023267B1 (es)
CA (1) CA2906931C (es)
DK (1) DK2988743T3 (es)
EA (1) EA033923B1 (es)
ES (1) ES2855173T3 (es)
MX (3) MX382748B (es)
PT (1) PT2988743T (es)
SG (3) SG10201803833WA (es)
WO (1) WO2014145873A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000459B2 (en) * 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
AU2016355863A1 (en) * 2015-11-20 2018-07-05 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of nash
KR102292989B1 (ko) * 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
KR102698386B1 (ko) * 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
EP3728210B1 (en) * 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR102697358B1 (ko) * 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
WO2019126103A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
JP7202383B2 (ja) * 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112074515B (zh) * 2017-12-19 2025-01-10 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
JP7526096B2 (ja) * 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
KR20250107972A (ko) 2018-05-04 2025-07-14 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
CA3104465A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CN113366000A (zh) 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
WO2021076961A1 (en) * 2019-10-16 2021-04-22 University Of South Florida Compositions and methods of treatment for inhibiting capillary tube regression
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR102913125B1 (ko) 2020-06-03 2026-01-20 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
WO2022013378A1 (en) * 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors
MX2023001812A (es) * 2020-08-11 2023-06-19 Viva Star Biosciences Ltd Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.
CA3218917A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
KR20240115978A (ko) * 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
EP4622713A1 (en) * 2022-11-24 2025-10-01 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with lpa receptor activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
ATE420878T1 (de) 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
DE60234318D1 (de) 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
CN1863793A (zh) 2003-06-11 2006-11-15 三共株式会社 环状叔胺化合物
WO2005012269A1 (ja) 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
AU2004287849A1 (en) 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
CN1938273B (zh) 2004-03-26 2011-12-14 霍夫曼-拉罗奇有限公司 四氢咔唑类及衍生物
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
TW200803740A (en) * 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
EP2096111A1 (en) 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
WO2009051245A1 (ja) 2007-10-18 2009-04-23 Kumiai Chemical Industry Co., Ltd. ３－アルコキシ－１－フェニルピラゾ－ル誘導体及び有害生物防除剤
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (es) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
JP4683154B2 (ja) 2009-08-12 2011-05-11 横浜ゴム株式会社 冷媒移送用ホース
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
US20120031985A1 (en) 2010-08-09 2012-02-09 Terry Lien Do Fault tolerant appliance
PH12013501136A1 (en) 2010-12-07 2013-07-08 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and uses thereof
SG191041A1 (en) 2010-12-07 2013-08-30 Amira Pharmaceuticals Inc Polycyclic lpa1 antagonist and uses thereof
WO2012100436A1 (en) 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
EA201491530A1 (ru) 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
JP2015520203A (ja) 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｐａｒ拮抗薬としてのｎ−アリールトリアゾール化合物
EA201492285A1 (ru) 2012-06-20 2015-04-30 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201492283A1 (ru) 2012-06-20 2015-04-30 Ф. Хоффманн-Ля Рош Аг Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
ES2667798T3 (es) 2012-12-28 2018-05-14 Ube Industries, Ltd. Compuesto heterocíclico sustituido con halógeno
US20140213538A1 (en) 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2015066456A1 (en) 2013-10-31 2015-05-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
CA3104465A1 (en) 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease

Also Published As

Publication number Publication date
EP2988743B1 (en) 2020-12-09
EA201591607A1 (ru) 2016-05-31
JP2019081784A (ja) 2019-05-30
MX2015013303A (es) 2015-12-15
WO2014145873A2 (en) 2014-09-18
US20190135767A1 (en) 2019-05-09
AU2019202731A1 (en) 2019-05-16
DK2988743T3 (da) 2021-03-01
JP6843903B2 (ja) 2021-03-17
CA2906931C (en) 2023-03-14
MX2024011839A (es) 2024-11-08
PT2988743T (pt) 2021-03-03
US20160024031A1 (en) 2016-01-28
ES2855173T3 (es) 2021-09-23
CN112424174B (zh) 2024-02-27
AU2019288275A1 (en) 2021-01-28
BR112015023267B1 (pt) 2023-01-31
BR112015023267A2 (pt) 2017-07-18
CN105142635B (zh) 2021-07-27
MX2020014300A (es) 2021-05-12
EP2988743A4 (en) 2016-11-30
US10000459B2 (en) 2018-06-19
KR102090231B1 (ko) 2020-03-17
JP2016515536A (ja) 2016-05-30
EA033923B1 (ru) 2019-12-10
US20230286928A1 (en) 2023-09-14
JP2024084796A (ja) 2024-06-25
AU2019202731B2 (en) 2020-10-29
KR20150130415A (ko) 2015-11-23
SG10201803833WA (en) 2018-06-28
NZ712889A (en) 2020-10-30
SG11201507459YA (en) 2015-10-29
SG11202012656WA (en) 2021-01-28
AU2019288275B2 (en) 2024-08-01
WO2014145873A3 (en) 2014-12-18
CN118290357A (zh) 2024-07-05
HK1221167A1 (zh) 2017-05-26
JP6482086B2 (ja) 2019-03-13
BR112020025927A2 (pt) 2021-03-23
US11427552B2 (en) 2022-08-30
CN105142635A (zh) 2015-12-09
US20180297962A1 (en) 2018-10-18
BR112015023267A8 (pt) 2021-04-13
JP2026004456A (ja) 2026-01-14
AU2014232383B2 (en) 2019-01-17
CN112424174A (zh) 2021-02-26
EP2988743A2 (en) 2016-03-02
US10570103B2 (en) 2020-02-25
JP7754979B2 (ja) 2025-10-15
US10526298B2 (en) 2020-01-07
CA2906931A1 (en) 2014-09-18
AU2014232383A1 (en) 2015-10-01
EA201591607A8 (ru) 2018-03-30
US20200181099A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX382748B (es) Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
MX2019002439A (es) Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades.
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
AR086466A1 (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto activo insecticida o acaricida o nematicida
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JOP20210039A1 (ar) مركبات بيريدين 6،2 - ديامينو
ES2869910T8 (es) Preparación compuesta, que contiene un nuevo derivado de ácido 3-(4-(benciloxi)fenil)hex-4-inoico y otro principio activo, para prevenir o tratar enfermedades metabólicas
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
PE20151329A1 (es) Derivado de azol benceno
EA201892536A1 (ru) Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201692298A1 (ru) Производные карбоксамидов
GT201300089A (es) Nuevas formas cristalinas de la sal sodica del acido (4-(4-(5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il)-fenil)-ciclohexil)-acetico
MX2017000634A (es) Inhibidores del canal de potasio medularmente externo renal.
PE20211391A1 (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico